Cancer clinical trials in the region Provence-Alpes-Côte d'Azur
436 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Early Access
Bladder / Urinary Tract / Urethral cancer
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Astellas Pharma Développement mondial, Inc.
Early Access
Lymphoma
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required number of previous lines of therapy
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
1 recruiting site
Hoffmann-La Roche
Early Access
Lung cancer
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Janssen
Early Access
Acute leukemia
Required histologic types
Acute lymphoblastic leukemia (ALL)
Required histologic sub types
B-cell (B-ALL)
Required immunophenotypic profiles
CD19
Required number of previous lines of therapy
None
Required previous treatments
Chemotherapy
Excluded genetic anomalies
Ph+ (Philadelphia chromosome positive)
Excluded previous treatments
Systemic Treatment-Naive
1 recruiting site
Amgen
Early Access
Lung cancer
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Amgen
Phase 3
Stomach and esophageal cancer
#NCT06644781
#2023-509630-19-00
Required histologic types
Esophagus
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
12 recruiting sites
Daiichi Sankyo
Phase 3
Breast cancer
#NCT06492616
#2024-515445-42-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
21 recruiting sites
Stemline Therapeutics, Inc.
Phase 3
Chronic myeloid leukemia (CML)
#NCT06423911
#2024-511495-32-00
Partie B (Mutation T315I)
Required disease stage
Chronic phase
Required genetic anomalies
T315I
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
ATP pocket inhibitor
Allosteric inhibitor
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Ascentage Pharma Group Inc.
Phase 3
Chronic myeloid leukemia (CML)
#NCT06423911
#2024-511495-32-00
Partie A (Non-T315I)
Required disease stage
Chronic phase
Required number of previous lines of therapy
2
3 or more
Required previous treatments
ATP pocket inhibitor
Allosteric inhibitor
Excluded genetic anomalies
T315I
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Ascentage Pharma Group Inc.
Phase 3
Colon cancer
Rectal cancer
#NCT06107920
#2024-516456-17-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
Chemotherapy
Radiotherapy
28 recruiting sites
Hôpital universitaire de Rouen